As of 2025-04-18, the EV/EBITDA ratio of Prometheus Biosciences Inc (RXDX) is -58.45. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Prometheus's latest enterprise value is 9,445.47 mil USD. Prometheus's TTM EBITDA according to its financial statements is -161.61 mil USD. Dividing these 2 quantities gives us the above Prometheus EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 9.8x | 8.8x |
| Forward P/E multiples | 8.7x - 19.7x | 14.2x |
| Fair Price | (27.04) - (30.75) | (36.50) |
| Upside | -113.5% - -115.4% | -118.3% |
| Date | EV/EBITDA |